Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3858279

Drug Profile

GSK 3858279

Alternative Names: GSK3858279

Latest Information Update: 19 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories
  • Mechanism of Action Chemokine CCL17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 11 Oct 2019 GlaxoSmithKline plans a phase I trial for Pain in healthy male (In volunteers) in October 2019 (NCT04114656)
  • 17 May 2018 Phase-I clinical trials in Pain in United Kingdom (SC) (IV) (NCT03485365)
  • 06 Apr 2018 GlaxoSmithKline plans a phase I trial for Pain due to osteoarthritis of the Knee in USA (SC) (IV) (NCT03485365)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top